Cargando…
Impact of Drug Safety Warnings and Cost-Sharing Policies on Osteoporosis Drug Utilization in Spain: A Major Reduction But With the Persistence of Over and Underuse. Data From the ESOSVAL Cohort From 2009 to 2015
Background: Recent studies in several countries show a significant decrease in the consumption of osteoporosis drugs from a peak around 2009, mainly attributed to bisphosphonate safety warnings issued by regulatory agencies on jaw osteonecrosis, atypical fractures, and esophageal cancer, but no stud...
Autores principales: | Hurtado-Navarro, Isabel, García-Sempere, Aníbal, Rodríguez-Bernal, Clara, Sanfélix-Genovés, José, Peiró, Salvador, Sanfélix-Gimeno, Gabriel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635591/ https://www.ncbi.nlm.nih.gov/pubmed/31354484 http://dx.doi.org/10.3389/fphar.2019.00768 |
Ejemplares similares
-
Impact of a multifaceted intervention to improve the clinical management of osteoporosis. The ESOSVAL-F study
por: Sanfélix-Genovés, José, et al.
Publicado: (2010) -
Overuse and Underuse of Antiosteoporotic Treatments According to Highly Influential Osteoporosis Guidelines: A Population-Based Cross-Sectional Study in Spain
por: Sanfélix-Gimeno, Gabriel, et al.
Publicado: (2015) -
Trends and Geographical Variability in Osteoporosis Treatment After Hip Fracture: A Multilevel Analysis of 30,965 Patients in the Region of Valencia, Spain
por: Hurtado, Isabel, et al.
Publicado: (2020) -
Development and validation of a population-based prediction scale for osteoporotic fracture in the region of Valencia, Spain: the ESOSVAL-R study
por: Sanfélix-Genovés, José, et al.
Publicado: (2010) -
Adherence to and appropriateness of anti-osteoporotic treatments in patients aged 50 and over in the Valencia Region (Spain). The ESOSVAL-AD Study
por: Sanfélix-Gimeno, Gabriel, et al.
Publicado: (2011)